GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immix Biopharma Inc (NAS:IMMX) » Definitions » Total Current Liabilities

Immix Biopharma (Immix Biopharma) Total Current Liabilities : $3.72 Mil (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Immix Biopharma Total Current Liabilities?

Total current liabilities includes Accounts Payable & Accrued Expense, Short-Term Debt & Capital Lease Obligation, Other Current Liabilities, and Current Deferred Liabilities. Immix Biopharma's total current liabilities for the quarter that ended in Dec. 2023 was $3.72

Immix Biopharma Total Current Liabilities Historical Data

The historical data trend for Immix Biopharma's Total Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immix Biopharma Total Current Liabilities Chart

Immix Biopharma Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Total Current Liabilities
4.59 5.27 0.20 1.27 3.72

Immix Biopharma Quarterly Data
Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Total Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.27 1.47 2.40 2.83 3.72

Immix Biopharma Total Current Liabilities Calculation

Total Current Liabilities is the total amount of liabilities that the company needs to pay over the next 12 months.

Immix Biopharma's Total Current Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=3.722+0
+Other Current Liabilities+Current Deferred Liabilities
=0+0
=3.72

Immix Biopharma's Total Current Liabilities for the quarter that ended in Dec. 2023 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=3.722+0
+Other Current Liabilities+Current Deferred Liabilities
=0+0
=3.72

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.

Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

Immix Biopharma Total Current Liabilities Related Terms

Thank you for viewing the detailed overview of Immix Biopharma's Total Current Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Immix Biopharma (Immix Biopharma) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immix Biopharma Inc (NAS:IMMX) » Definitions » Total Current Liabilities
Comparable Companies
TLSA CARA CCCC ACXP GBIO NGM ATHA APLM XLO CASI OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
N/A
Address
11400 West Olympic Boulevard, Suite 200, Los Angeles, CA, USA, 90064
Website
https://www.immixbio.com
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. It has two business units ImmixBio and Nexcella.
Executives
Jason Hsu director 11400 WEST OLYMPIC BLVD., SUITE 200, LOS ANGELES CA 90064
Carey Ng director 11400 WEST OLYMPIC BLVD., SUITE 200, LOS ANGELES CA 90064
Helen C. Adams director 15378 AVENUE OF SCIENCE, STE 100, SAN DIEGO CA 92128
Melissa Jane Buchan director 1920 MAIN STREET, SUITE 500, IRVINE CA 92614
Magda Marquet director ALTHEADX INC., 3550 DUNHILL STREET, SAN DIEGO CA 92121
Yekaterina Chudnovsky director, 10 percent owner C/O ELICIO THERAPEUTICS, INC., 451 D STREET, 5TH FLOOR, SUITE 501, BOSTON MA 02210
Ilya M Rachman director, officer: CEO and Chairman 11400 WEST OLYMPIC BLVD.,, SUITE 200, LOS ANGELES CA 90064
Gabriel S Morris director, officer: Chief Financial Officer 11400 WEST OLYMPIC BLVD.,, SUITE 200, LOS ANGELES CA 90064
Sean Senn 10 percent owner 11400 WEST OLYMPIC BLVD., SUITE 200, LOS ANGELES CA 90064
Vladimir P Torchilin officer: Scientific Co-Founder 11400 WEST OLYMPIC BLVD.,, SUITE 200, LOS ANGELES CA 90064
Graham Ross officer: CMO & Head of Clinical Dev. 11400 WEST OLYMPIC BLVD., SUITE 200, LOS ANGELES CA 90064

Immix Biopharma (Immix Biopharma) Headlines

From GuruFocus

Immix Biopharma Subsidiary Nexcella Completes Initial NXC-201 Engineering Batch at its U.S. CAR-T Manufacturing Site

By Marketwired • 07-10-2023

Immix Biopharma Subsidiary Nexcella Appoints Edward J. Borkowski, former Chief Financial Officer of Mylan N.V, to Board of Directors

By Marketwired • 06-22-2023

Director Helen Adams Buys 13,000 Shares of Immix Biopharma Inc (IMMX)

By GuruFocus Research • 09-15-2023

Immix Biopharma Announces Early Positive IMX-110 Interim Clinical Trial Data Demonstrating 100% Tumor Shrinkage in Advanced Metastatic Colorectal Cancer at the Lowest Dose of IMX-110 + BeiGene / Novartis Anti-PD-1 Antibody Tislelizumab

By sperokesalga sperokesalga • 05-03-2023

Immix Biopharma Subsidiary Nexcella Completes Pre-IND Meeting with FDA on NXC-201 US Clinical Trial

By Marketwired • 06-26-2023

U.S. Food and Drug Administration Approves Orphan Drug Designation for Immix Biopharma NXC-201 as a Treatment for Multiple Myeloma

By Marketwired • 08-23-2023

Immix Biopharma Reports 2nd Positive Interim Clinical Trial Data Readout in Relapsed/Refractory Metastatic Colorectal Cancer in Ongoing Phase 1b/2a IMX-110 IMMINENT-01 Clinical Trial

By Marketwired • 07-17-2023

Nexcella, an Immix Biopharma Subsidiary, Announces 2023 Haematologica Editorial Highlighting NXC-201 Efficacy In The Context of U.S. Food And Drug Administration Approved BCMA CAR T Cells

By sperokesalga sperokesalga • 03-31-2023

Immix Biopharma Subsidiary Nexcella Announces NXC-201 Multiple Myeloma Clinical Data Abstract Accepted for Presentation at the 20th International Myeloma Society Annual Meeting

By Marketwired • 07-25-2023

Nexcella Announces Positive NXC-201 Clinical Results at ASGCT: 100% Overall Response Rate in DARZALEX-Relapsed/Refractory AL Amyloidosis with Zero ICANs in Ongoing NEXICART-1 Phase 1b/2a Clinical Trial

By sperokesalga sperokesalga • 05-21-2023